Ovarian Cancer

Intratumoral mRNA-2416, a lipid nanoparticle therapeutic agent expressing the wild-type human OX40L, appeared safe among a cohort of patients with locally advanced, recurrent or metastatic solid tumors, according to results of a phase 1/2 first-in-human study presented at the virtual American Association for Cancer Research Annual Meeting.

The US Oncology Network named Robert L. Coleman, MD, FACOG, FACS, its new chief scientific officer.

Breastfeeding appeared to be associated with reduced risk for overall ovarian cancer and for the high-grade serous subtype, according to results of a pooled analysis published in JAMA Oncology.

A novel blood test accurately detected more than 50 types of cancer with a specificity of 99.3%, according to results of the prospective Circulating Cell-free Genome Atlas study published in Annals of Oncology.

The combination of cediranib and olaparib failed to extend PFS compared with platinum-based chemotherapy for a subset of women with ovarian cancer, according to topline results of a randomized phase 3 trial.

The FDA accepted a supplemental new drug application for niraparib as first-line maintenance treatment of women with platinum-responsive advanced ovarian cancer.

Insight into how clinicians can integrate belief in miracles into their discussions with terminally ill patients with advanced cancer was the top story in hematology/oncology last week.

The FDA granted priority review to olaparib in combination with bevacizumab as first-line maintenance treatment of women with advanced ovarian cancer, according to the agent’s manufacturer.

Researchers did not find a significantly higher risk for ovarian cancer in women who used powder in the genital area, according to an analysis of more than 250,000 women recently published in JAMA.

CA-125 is a “useful test” for ovarian cancer in primary care, especially in symptomatic women aged older than 50 years, according to a presenter at the recent National Cancer Research Institute Cancer Conference in Glasgow.